Portal de Periódicos da CAPES

Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with ¹⁷⁷Lu and Conjugated to Peptides

2015; Bentham Science Publishers; Volume: 8; Issue: 2 Linguagem: Inglês

10.2174/1874471008666150313115423

1874-4729

Guillermina Ferro‐Flores, Blanca Ocampo‐García, Clara Santos‐Cuevas, Flor María Ramírez, Erika Azorín‐Vega, Laura Meléndez‐Alafort,

Radioactive Decay and Measurement Techniques

Gold nanoparticles (AuNPs) have been proposed for a variety of medical applications such as localized heat sources for cancer treatment and drug delivery systems. The conjugation of peptides to AuNPs produces stable multimeric systems with target-specific molecular recognition. Lutetium- 177 ((177)Lu) has been successfully used in peptide radionuclide therapy. Recently, (177)Lu-AuNPs conjugated to different peptides have been proposed as a new class of theranostic radiopharmaceuticals. These radioconjugates may function simultaneously as molecular imaging agents, radiotherapy systems and thermal-ablation systems. This article covers advancements in the design, synthesis, physicochemical characterization, molecular recognition assessment and preclinical therapeutic efficacy of gold nanoparticles radiolabeled with (177)Lu and conjugated to RGD (-Arg-Gly-Asp-), Lys(3)-Bombesin and Tat(49-57) peptides.